?The bone and joint health supplements market continues to rise due to the growing aging population here in the U.S. and we believe BioCalth is unlike any supplement out there in the marketplace today. We are excited that these retailers also sees the potential of BioCalth in the U.S. market and we look forward to what we believe will be a successful brand for many years to come,? stated Chairman of LTS Nutraceuticals, Ted Farnsworth.
BioCalth® is a unique, patented Calcium L-Threonate supplement that is scientifically proven to improve bone density and encourage the formulation of cartilage and collagen to strengthen bones.* BioCalth is currently sold in some of the largest drug store chains in Asia including Watson?s, Unity and Guardian, as well as in Europe. The U.S. market is the largest bone health and joint health market in the world. According to an article in News-Medical.Net (September 2011), the bone and joint health supplements market is forecasted to be worth over $9 billion by 2017 worldwide1.
1http://www.news-medical.net/news/20110929/Bone-and-joint-health-supplements-market-to-be-worth-over-249-billion-by-2017.aspx
*These products have not been evaluated by the FDA and are not intended to diagnose, treat, cure, or prevent any disease.
About LTS Nutraceuticals, Inc.
Headquartered in Ft. Lauderdale, FL, LTS Nutraceuticals, Inc. develops, manufactures, markets and distributes an expanding line of unique, high-quality vitamins, vitamin boosters, dietary supplements and nutraceuticals. The products are sold throughout North America through two marketing channels: direct selling utilizing Inline Marketing? to introduce products to the consumer and marketing products through national retail, drug and grocery chains and club stores.
More information about the Company, visit: www.LTSNinc.com.
Forward-Looking Statements
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements contained in this release that are not historical facts, including, without limitation, statements that relate to the Company's expectations with regard to the future impact on the Company's results from new products in development, may be deemed to be forward-looking statements. Words such as "expects", "intends", "plans", "may", "could", "should", "anticipates", "likely", "believes" and words of similar import also identify forward-looking statements. These statements are subject to risks and uncertainties. Forward-looking statements are based on current facts and analyses and other information that are based on forecasts of future results, estimates of amounts not yet determined and assumptions of management. Readers are urged not to place undue reliance on the forward-looking statements, which speak only as of the date of this release. Except as may be required under applicable law, we assume no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release. Additional information on risks and other factors that may affect the business and financial results of LTS Nutraceuticals, Inc. can be found in the filings of LTS Nutraceuticals, Inc. with the U.S. Securities and Exchange Commission.


Forum
Facebook
Twitter





















